Paratek Pharmaceuticals Stock News

- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2021 Results - Earnings Call Transcript

Paratek (PRTK) delivered earnings and revenue surprises of -77.27% and -49.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 40.91% year over year to ($0.39), which missed the

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav

BOSTON, March 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2020 Results - Earnings Call Transcript

Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi

BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi